Last reviewed · How we verify
Epoetin alfa 3 times weekly /once weekly
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients with HIV infection on antiretroviral therapy.
At a glance
| Generic name | Epoetin alfa 3 times weekly /once weekly |
|---|---|
| Also known as | PROCRIT |
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This leads to increased reticulocyte production and elevated hemoglobin levels. The drug is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions causing reduced red blood cell production.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients receiving chemotherapy
- Anemia in patients with HIV infection on antiretroviral therapy
Common side effects
- Hypertension
- Headache
- Thrombotic events (stroke, myocardial infarction, deep vein thrombosis)
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) (PHASE3)
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (PHASE3)
- The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (PHASE2)
- A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis (PHASE2)
- Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (PHASE2)
- Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (PHASE3)
- Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: